Hematological Malignancies Market to be Driven by Rising Focus Towards R&D for Hematological Malignancies Treatments

Hematological malignancies or blood cancers are derived from the cells of blood forming tissue. It has observed that most of the blood cancers start in the bone marrow and can affect the production and function of blood. Stem cells present in our bone marrow develops into three types of blood cells namely red blood cells, white blood cells and platelets. During hematological malignancies uncontrolled growth of abnormal blood cells takes place in the bone marrow. These abnormal blood cells unable to prevent infections caused to our body. Example of hematological malignancies includes leukemia, lymphoma and myeloma.

Request Sample of Research Report: http://bit.ly/2eVTqqv

Leukemia is caused by rapid production of abnormal white blood cells in our body whereas lymphoma is a cancer of lymph system which is a part of our immunity. Lymphoma is one of the major chronic diseases related to blood systems. It is developed from excessive growth of lymphocytes in the blood. The disease is differentiated into various subtypes, such as Hodgkin lymphoma, non-Hodgkin lymphoma and many others. Myeloma is a cancer of the plasma cells. Plasma cells are white blood cells that produce disease and infection fighting antibodies in your body.

The market is segmented on the basis of treatments available, such as, chemotherapy, surgical treatment and radiation therapy. Chemotherapy usually includes multi-drug combination therapy, which include drugs such as doxorubicin, cyclophosphamide, prednisolone, vincristine, etoposide, and others. In addition, new drugs include pralatrexate, bexarotene, gemcitabine, romidepsin and others. Surgical treatment is mainly used to transplant bone marrow or stem-cell transplantation, since the bone marrow treatment has proved its effectiveness in the treatment of blood related cancers. In case of radiation therapy, the high power gamma or X-ray are used to treat the disease.

The market of hematological malignancies is expressed to show steady growth rate during the forecast period from 2014 – 2020. This growth is driven by major factors, such as rising prevalence of various diseases and extensive R&D practices are ongoing across the globe to bring new and more effective drugs and formulations in the market. Further, due to extensive R&D practices, a number of drugs and formulations are under pipeline studies.

New therapy and drugs such as, histone deacetylase (HDAC) inhibitors, immunomodulatory drugs and proteasome inhibitors are under pipeline study and expected to enter in the market during forecast period. These drivers are anticipated to accentuate the growth of the market. These drivers are coupled with other important factors such as, increasing medical infrastructure and rising awareness about the disease. Major restraints of the market include high cost of the diagnosis and treatment. Further, due to less penetration of technologically advanced diagnostic devices in certain regions of the world, the growth of the market is expected to restrict to some extent.

The North American region is the most dominating market in the world, owing to rapidly growing incidences of lymphoma cancers and rising focus towards R&D for hematological malignancies treatments. For instance, Lymphoma Research Foundation stated that, T-cell lymphomas accounted for approximately 15% of all non-Hodgkin lymphomas in the U.S. every year.

Browse Research Report: http://bit.ly/2eVMUQI

On the other hand, Asia-Pacific and RoW region are the most promising markets in the upcoming period, owing to rise in awareness of blood cancers and its chronic impacts along with its treatments.

Some of the major players operating in this market include Takeda Pharmaceutical Company Limited, Celgene Corporation, AbbVie, Inc., Pfizer, Inc. and many others.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.